The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1615
ISSUE1615
January 11, 2021
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
January 11, 2021 (Issue: 1615)
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.